FRAXEL III SR LASER SYSTEM AND ACCESSORIES

K071051 · Reliant Technologies, Inc. · GEX · Nov 2, 2007 · General, Plastic Surgery

Device Facts

Record IDK071051
Device NameFRAXEL III SR LASER SYSTEM AND ACCESSORIES
ApplicantReliant Technologies, Inc.
Product CodeGEX · General, Plastic Surgery
Decision DateNov 2, 2007
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 878.4810
Device ClassClass 2
AttributesTherapeutic

Intended Use

The Fraxel III SR (Fraxel re:pair™) Laser System is intended for use in: Dermatological procedures requiring ablation (removal), resurfacing and coagulation of soft tissue. Treatment of wrinkles, rhytides, furrows, fine lines, texture irregularities, pigmented lesions and vascular dyschromia.

Device Story

Fraxel III SR Laser System is a laser surgical instrument for dermatological procedures. Device utilizes a laser source to deliver thermal energy to epidermis and dermis via scanning and focusing optics. Interchangeable treatment tips are used to apply energy. System performs ablation, resurfacing, and coagulation of soft tissue. Operated by clinicians in a professional setting. Output allows for treatment of skin conditions like wrinkles, rhytides, and pigmented lesions. Clinical benefit includes improved skin texture and appearance through controlled tissue removal and coagulation.

Clinical Evidence

Safety and effectiveness supported by Non-Significant Risk and Investigational Device Exemption (IDE) studies. Clinical data demonstrated the device performed as intended with no new safety or effectiveness issues identified.

Technological Characteristics

Laser surgical instrument; utilizes laser source with scanning and focusing optics to deliver thermal energy. Includes interchangeable treatment tips. Energy type and operating principle equivalent to predicate Fraxel SR and Lumenis UltraPulse systems.

Indications for Use

Indicated for dermatological procedures requiring ablation, resurfacing, and coagulation of soft tissue, including treatment of wrinkles, rhytides, furrows, fine lines, textural irregularities, pigmented lesions, and vascular dyschromia.

Regulatory Classification

Identification

(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ # 07105 ### NOV = 2 2007 ### 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS ### REGULATORY AUTHORITY Safe Medical Devices Act of 1990, 21 CFR 807.92 ### COMPANY NAME/CONTACT Heather MacFalls Reliant Technologies, Inc. 464 Ellis St. Mountain View, CA 94043 650 605-2257 650 605-2057 fax hmacfalls@fraxel.com ### NAME OF DEVICE Trade Name: Common Name: Regulation Number Product code: Device Panel: Device Classification: Fraxel III SR Laser System (Fraxel re:pair™) and Accessories Laser Surgical Instrument 878.4810 GEX General Surgery/Restorative Devices Class II ### LEGALLY MARKETED PREDICATE DEVICES Name: Fraxel SR Laser System and Accessories 510(k) #: K053047, K050841, K042319, K040617 and K031795 Name: Fraxel II SR Laser System and Accessories 510(k) #: K062303 Name: Fraxel III SR Lascr System and Accessories 510(k) #: K063038 Name: Lumenis UltraPulse Encore Carbon Dioxide Surgical Laser and Delivery Device Accessories 510(k) #: K022060, K030147 #### DEVICE DESCRIPTION The Fraxel III SR Laser System consists of a laser source which delivers a pattern of thermal energy to the epidermis and dermis using scanning and focusing optics. Device accessories include interchangeable treatment tips. {1}------------------------------------------------ 0710j1 ### INDICATION FOR USE STATEMENT The Fraxel III SR (Fraxel re:pair™) Laser System is intended for use in: Dermatological procedures requiring ablation (removal), resurfacing and coagulation of soft tissue. Treatment of wrinkles, rhytides, furrows, fine lines, texture irregularities, pigmented lesions and vascular dyschromia. ### SUBSTANTIAL EQUIVALENCE COMPARISON #### Indications for Use Substantial equivalence for the Fraxel III SR (Fraxel re:pair) Laser System and Accessories is supported by the predicate devices listed in this submission, which have identical or similar indication statements. ### Clinical Performance Data Non-Significant Risk and Investigational Device Exemption studies support the clinical performance of the Fraxel III SR (Fraxel re:pair) Laser System. Sufficient clinical data supported the determination of safety and effectiveness for the Fraxel III SR (Fraxel re:pair) Laser System and Accessories. The device performed as clinically intended with no new issues of safety and effectiveness introduced. #### Technological Characteristics Key technological characteristics of the Fraxel III SR (Fraxel re:pair) Laser System, such as energy type and operating principle, are equivalent to the Fraxel SR Laser System as described in submissions K053047, K050841, K042319, K040617 and K031795, to the Fraxel II SR Laser System as described in K062303 and to the Lumenis Ultrapulse Encore Laser System as described in K020660 and K030147. ### CONCLUSION Based on the design, materials, function, intended use and clinical evaluation, the Fraxel III (Fraxel re:pair) Laser System and Accessories is substantially equivalent to the devices currently marketed under the Federal Food, Drug and Cosmetic Act. Safety and effectiveness are reasonably assured, justifying 510(k) clearance. {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features the department's name in a circular arrangement around a stylized symbol. The symbol is a graphic representation of a human figure, with three abstract shapes forming the head, body, and legs. The logo is simple and recognizable, representing the department's focus on health and human well-being. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 NOV - 2 2007 Reliant Technologies, Inc. % Ms. Heather MacFalls Clinical and Regulatory Affairs 464 Ellis Street Mountain View, California 94043 Re: K071051 Trade/Device Name: Fraxel III SR Laser System (Fraxel re:pair™) and Accessories Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: II Product Code: GEX Dated: August 1, 2007 Received: August 7, 2007 Dear Ms. MacFalls: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced aboye and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as setforth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the {3}------------------------------------------------ Page 2 - Ms. Heather MacFalls electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, For Off- Oct 06 li.17 Mark N. Melkerson Director Division of General, Restorative. and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ ## Indications for Use 510(k) Number (if known): Fraxel III SR Laser System (Fraxel re:pair™) and Accessories Device Name: Indications For Use: "The Fraxel III SR Laser System and accessories is intended for use in: Dermatological procedures requiring ablation (removal), resurfacing and coagulation of soft tissue. Treatment of wrinkles, rhytides, furrows, fine lines, textural irregularities, pigmented lesions and vascular dyschromia." Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) No **Division Si** Division Sign-Of Division of General, Restorative age 1 of 1 and Neurological Devices **510(k) Number** `co7105
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%